everolimus + enteric-coated mycophenolate sodium

A combination of **everolimus**, an mTOR (mechanistic Target of Rapamycin) inhibitor, and **enteric-coated mycophenolate sodium** (EC-MPS), a prodrug that delivers mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase (IMPDH). This combination is used as a **dual immunosuppressive regimen**, primarily studied in solid organ transplantation, such as kidney and liver transplants, to prevent organ rejection. Everolimus acts by inhibiting T cell proliferation and activity through mTOR pathway inhibition, while EC-MPS inhibits lymphocyte proliferation by blocking de novo guanine nucleotide synthesis. The combination is often designed to minimize or avoid the use of calcineurin inhibitors to reduce nephrotoxicity and other adverse effects. Clinical studies show this regimen is feasible and safe, presenting an alternative to traditional calcineurin inhibitor-based therapies[2][3][4].

Other names

everolimus + EC-MPS